Effects of simvastatin on myocardial fibrosis in NO-deficient hypertensive rats

Abstract

Abstract: AIM: To investigate the effects of simvastatin on myocardial fibrosis in NO-deficient hypertensive rats. METHODS: Twenty-four male Wistar-Kyoto rats were divided into three groups: Control ( C) group, L-NAME ( L) group, and L-NAME plus Simvastatin ( L +S) group. The levels of ACE and Ang Ⅱ in plasma and myocardial tissue, and the contents of hydroxyproline concentration in myocardial tissue were measured after 8 weeks. The values of CVF, PVCA and the hydroproline concentration ( HC ) were studied using the methods of pathological examination combined with computed processing. RESULTS: The activity of ACE in serum in L group was lower than that in C group ( P <0. 01). Simvastatin treatment did not significantly increase the activity of ACE compared with L group ( P >0. 05). However, the activity of ACE in myocardial tissue was lower than that of C group ( P <0. 05). Although the levels of Ang Ⅱ in plasma were not altered by L-NAME ( P >0. 05), the concentrations of Ang Ⅱ in myocardial tissue ( P < 0. 01) were significantly increased in L group compared to C group. Simvastatin significantly decreased the levels of Ang Ⅱ in myocardial tissue ( P <0. 05). The hydroxyproline concentration and the value of PVCA and CVF in L group were significantly higher than that in C group ( P <0. 01), which were significantly attenuated by simvastatin tratment ( P <0. 05). CONCLUSION: Simvastatin may decrease the production of Ang Ⅱ and attenuate myocardial fibrosis via reducing the activity of ACE in NOdeficient hypertensive rats.

Key words: simvastatin, angiotensin Ⅱ, myocardial fibrosis, angiotensin-converting enzyme, hypertension, NOS inhibitor

CLC Number:

R971
R965

YI Chun-Tao, CHENG Xiao-Shu, YU Jian-Hua, YAN Ding-Hong, SU Hai, WU Qing-Hua. Effects of simvastatin on myocardial fibrosis in NO-deficient hypertensive rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(4): 306-310.

References

1 Takewakis S, Kuro-o M, Hiroi Y, et al. Activation of Na⁺- H⁺ antiporter ( NHE-1) gene expression during growth hypertrophy and proliferation of the rabbit cardiovascular system[J]. J Mol Cell Cardiol, 1995;27: 729-42
2 Weber KT, Brilla CG, Janicki JS.Myocardial fibrosis functional significance and regulatory factors[J]. Cardiovasc Res, 1993; 27: 341-7
3 Davignon J, Laaksonen R.Low-density lipoprotein-independent effects of statins[J]. Curr Opin Lipodol, 1999;10: 543
4 Oi S, Haneda J, Osaki J, et al. Lovastatin prevents angiotensin Ⅱ-induced cardiac hypertrophy in cultured neonatal rat heart cells[J]. Eur J pharmacol, 1999;376:139-46
5 Brilla CG.Renin-angiotensin-aldosterone system and myocardial fibrosis[J]. Cardiovasc Res, 2000;47:1-3
6 Sadoshima J, Izumo S.Molecular charac-terization of angiotensin Ⅱ-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts.Critical role of the AT1 receptor subtype[J]. Cir Res, 1993; 73:413-8
7 Unger T, Ganten D, Lang RE, et al. Effect of converting enzyme inhibitors on tissue converting enzyme and angiotensin Ⅱ: therapeatic implication[J]. Am J Cardiol, 1987;59: 18D-22D
8 Kobayashi N, Hara K, Watanabe S, et al. Effect of imidapril on myocardial remodeling in L-NAME-induced hypertensive rats is associated with gene expression of NOS and ACE mRNA[J]. Am J Hypertens, 2000;13: 199-207
9 Henrion D, Dechaux Em, Dowell FJ, et al. Alteration of flowinduced dilataration in mesenreric resistance arteries of L-NAME treated rats and its partial association with induction of cyclooxygenase- 2[J]. Br J Pharmacol, 1997; 121:83-90
10 易春涛, 程晓曙, 俞建华, 等.辛伐他汀对一氧化氮缺乏性高血压大鼠心脏局部肾素血管紧张素系统的影响.中国临床药理学与治疗学[J]. 2002;7: 227-30
11 Ohta K, Kims S, Wanibuchi D, et al. Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR( mRen2) 27 transgenic rats [J]. Circulation, 1996; 94:785-91
12 Chih-chang W, Meng QC, Palmer R, et al. Evidence for Angiotensin- converting enzyme- and chymase-mediated angiotensin Ⅱ formation in the interstitial fluid space of the dog heart in vivo[J]. Circulation, 1999;99:2583-9
13 Mitani H, Bandoh T, Ishikawa J, et al. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits[J]. Br J Pharmacol, 1996;119:1269-75
14 Takewakis S, Kuro-o M, Hiroi Y, et al. Activation of Na⁺- H⁺ antiporter ( NHE-1) gene expression during growth, hypertrophy and proliferation oftherabbitcardiovascular system[J]. J Mol Cell Cardiol, 1995; 27:729-42

[1]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[2]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[3]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[4]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[5]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[6]	CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
[7]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[8]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[9]	KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
[10]	LIU Guijian, CHENG Kuan, ZHU Wenqing, GE Junbo. Progress of hypertension pharmacological treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 446-449.
[11]	NIU Pilian, FAN Yongxin, LU Furui, ZHOU Xuezhang, BAI Mingsheng. Effects of liquorice extract on cardiac fibroblasts fibrosis induced by TGF-β1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 129-135.
[12]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
[13]	JIA Chengwen, JIANG Hugang, GAO Xiang, HAN Jinyan, XU Xiaodong, ZHAO Xinke. Interventional effect of Radix Angelica Sinensis and Radix Hedysari ultrafiltration on miR-21-5P targeting TGF-β1-mediated radiation-induced myocardial fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1221-1230.
[14]	TANG Jiawei, MENG Xiangzhe, SUN Xuemin, LI Yuexuan, LIU Xue, WEI Hong. Role of vitamin D and ACE2 in COVID-19 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1292-1298.
[15]	WANG Rui, PAN Jinjin, LI Hua, YUAN Yuhui. Research progress of melatonin on pulmonary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 444-448.